Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction modified FOLFIRINOX followed by S-1 chemoradiation in locally advanced pancreatic cancer
jRCTs051210101Phase 2Active, not recruiting
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of FOLFIRINOX and tegafur in pancreatic adenocarcinoma (PDAC). Primary endpoint: Overall Response Rate. Started Nov 2021; status: active, not recruiting.
02
Drugs
FOLFIRINOXtegafur
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCTs051210101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051210101.